Recent developments in the use of biologics targeting IL-5, IL-4, or IL-13 in severe refractory asthma

References

• Papi A, Brightling C, Pedersen SE, et al. Asthma. Lancet. 2018 Feb 24;391(10122):783–800.
   PubMed Web of Science ®Google Scholar
• McCracken JL, Veeranki SP, Ameredes BT, et al. diagnosis and management of asthma in adults: a review. JAMA. 2017;18(318):279–290.
   Google Scholar
• Barnes PJ. Targeting cytokines to treat asthma and chronic obstructive pulmonary disease. Nat Rev Immunol. 2018 Apr 6;18:454–466. Epub ahead of print. .
   PubMed Web of Science ®Google Scholar
• Ray A, Oriss TB, Wenzel SE. Emerging molecular phenotypes of asthma. Am J Physiol Lung Cell Mol Physiol. 2015;308:L130–40.
   PubMed Web of Science ®Google Scholar
• Lotvall J, Akdis CA, Bacharier LB, et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol. 2011;127(2):355–360.
   PubMed Web of Science ®Google Scholar
• Arron JR, Choy DF, Scheerens H, et al. Non-invasive biomarkers that predict treatment benefit from biologic therapies in asthma. Ann Am Thorac Soc. 2013;10(Suppl):S206–13.
   PubMedGoogle Scholar
• Rosenberg HF, Dyer KD, Foster PS. Eosinophils: changing perspectives in health and disease. Nat Rev Immunol. 2013;13(1):9–22.
   PubMed Web of Science ®Google Scholar
• Nissim Ben Efraim AH, Levi-Schaffer F. Tissue remodelling and angiogenesis in asthma: the role of the eosinophil. Ther Adv Respir Dis. 2008;2:163–171.
   PubMedGoogle Scholar
• Talini D, Novelli F, Bacci E, et al. Sputum eosinophilia is a determinant of FEV1 decline in occupational asthma: results of an observational study. BMJ Open. 2015;5:e005748.
   PubMed Web of Science ®Google Scholar
• Price D, Wilson AM, Chisholm A, et al. Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice. J Asthma Allergy. 2016;9:1–12.
   PubMed Web of Science ®Google Scholar
• Ortega H, Yancey SW, Keene ON, et al. Asthma exacerbations associated with lung function decline in patients with severe eosinophilic asthma. J Allergy Clin Immunol Pract. 2018;6:980–986.
   PubMed Web of Science ®Google Scholar
• Robinson DS. Mepolizumab for severe eosinophilic asthma. Expert Rev Respir Med. 2013;7:13–17.
   PubMed Web of Science ®Google Scholar
• Walsh GM. Reslizumab in the treatment of severe eosinophilic asthma: an update. Immunotherapy. 2018 Mar 20. Epub ahead of print. DOI:10.2217/imt-2017-0176.
   PubMed Web of Science ®Google Scholar
• Corren J. Inhibition of interleukin-5 for the treatment of eosinophilic diseases. Discov. 2012;13:305–312.
   Google Scholar
• Ghazi A, Trikha A, Calhoun WJ. Benralizumab–a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity–a novel approach for the treatment of asthma. Expert Opin Biol Ther. 2012;12:113–118.
   PubMed Web of Science ®Google Scholar
• Walsh GM. Mepolizumab based therapy in Asthma – an update. Curr Opin Allergy Clin Immunol. 2015;15:392–396.
   PubMed Web of Science ®Google Scholar
• Menzella F, Lusuardi M, Montanari G, et al. Clinical usefulness of mepolizumab in severe eosinophilic asthma. Ther Clin Risk Manag. 2016;12:907–916.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380:651–659.
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371:1198.
   PubMed Web of Science ®Google Scholar
• Ortega HG, Yancey SW, Mayer B, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. 2016;4:549–556.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang S, Li DW, et al. Efficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a meta-analysis of randomized placebo-controlled trials. PLoS One. 2013;8:e59872.
   PubMed Web of Science ®Google Scholar
• Yancey SW, Ortega HG, Keene ON, et al. Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma. J Allergy Clin Immunol. 2016 Oct 4. S0091-6749(16)30891-0. Epub ahead of print. DOI: 10.1016/j.jaci.2016.08.008.
   PubMed Web of Science ®Google Scholar
• Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5:390–400.
   PubMed Web of Science ®Google Scholar
• Cockle SM, Stynes G, Gunsoy NB, et al. Comparative effectiveness of mepolizumab and omalizumab in severe asthma: an indirect treatment comparison. Respir Med. 2017;123:140–148.
   PubMed Web of Science ®Google Scholar
• Menzella F, Galeone C, Lusuardi M, et al. Near-fatal asthma responsive to mepolizumab after failure of omalizumab and bronchial thermoplasty. Ther Clin Risk Manag. 2017;13:1489–1493.
   PubMed Web of Science ®Google Scholar
• Whittington MD, McQueen RB, Ollendorf DA, et al. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis. Ann Allergy, Asthma, Immunol. 2017;118(2):220–225.
   PubMed Web of Science ®Google Scholar
• Castro M, Mathur S, Hargreave F, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011;184:1125–1132.
   PubMed Web of Science ®Google Scholar
• Bateman ND, Shahi A, Feeley KM, et al. Activated eosinophils in nasal polyps: a comparison of asthmatic and non-asthmatic patients. Clin Otolaryngol. 2005;30:221–225.
   PubMed Web of Science ®Google Scholar
• Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3:355–366.
   PubMed Web of Science ®Google Scholar
• Corren J, Weinstein S, Janka L, et al. Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest. 2016;150:799–810.
   PubMed Web of Science ®Google Scholar
• Bjermer L, Lemiere C, Maspero J, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest. 2016;150:789–798.
   PubMed Web of Science ®Google Scholar
• Chung KF. Defining phenotypes in asthma: a step towards personalized medicine. Drugs. 2014;74:719–728.
   PubMed Web of Science ®Google Scholar
• Brusselle G, Germinaro M, Weiss S, et al. Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils. Pulm Pharmacol Ther. 2017;43:39–45.
   PubMed Web of Science ®Google Scholar
• Murphy K, Jacobs J, Bjermer L, et al. Long-term safety and efficacy of reslizumab in patients with eosinophilic asthma. J Allergy Clin Immunol Pract. 2017;5:1572–1581.
   PubMed Web of Science ®Google Scholar
• Kolbeck R, Kozhich A, Koike M, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010;125:1344–1353.
   PubMed Web of Science ®Google Scholar
• Laviolette M, Gossage DL, Gauvreau G, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol. 2013;132:1086–1096.
   PubMed Web of Science ®Google Scholar
• Nowak RM, Parker JM, Silverman RA, et al. A randomized trial of benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, after acute asthma. Am J Emerg Med. 2015;33:14–20.
   PubMed Web of Science ®Google Scholar
• Castro M, Wenzel SE, Bleecker ER, et al. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med. 2014;2:879–890.
   PubMed Web of Science ®Google Scholar
• Pham TH, Damera G, Newbold P, et al. Reductions in eosinophil biomarkers by benralizumab in patients with asthma. Respir Med. 2016;111:21–29.
   PubMed Web of Science ®Google Scholar
• Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388:2115–2127.
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388:2128–2141.
   PubMed Web of Science ®Google Scholar
• Chipps BE, Newbold P, Hirsch I, et al. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma. Ann Allergy Asthma Immunol. 2018;120:504–511.
   PubMed Web of Science ®Google Scholar
• Goldman M, Hirsch I, Zangrilli JG, et al. The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies. Curr Med Res Opin. 2017;33:1605–1613.
   PubMed Web of Science ®Google Scholar
• Ohta K, Adachi M, Tohda Y, et al. Efficacy and safety of benralizumab in Japanese patients with severe, uncontrolled eosinophilic asthma. Allergol Int. 2018;67:266–272.
   PubMed Web of Science ®Google Scholar
• Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376(25):2448–2458.
   PubMed Web of Science ®Google Scholar
• Ferguson GT, FitzGerald JM, Bleecker ER, et al. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double blind, placebo-controlled, phase 3 trial. The Lancet RespiratoryMedicine. 2017;5:568–576.
   PubMed Web of Science ®Google Scholar
• Wills-Karp M, Luyimbazi J, Xu X, et al. Interleukin-13: central mediator of allergic asthma. Science. 1998;282:2258–2260.
   PubMed Web of Science ®Google Scholar
• Jia G, Erickson RW, Choy DF, et al. Bronchoscopic exploratory research study of biomarkers in corticosteroid refractory asthma (BOBCAT) study group. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol. 2012;130:647–654.
   PubMed Web of Science ®Google Scholar
• Piper E, Brightling C, Niven R, et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J. 2013;4:330–338.
   Web of Science ®Google Scholar
• Hanania NA, Noonan M, Corren J, et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax. 2015;70:748–756.
   PubMed Web of Science ®Google Scholar
• Hanania NA, Korenblat P, Chapman KR, et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2016;4:781–796.
   PubMed Web of Science ®Google Scholar
• Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368:2455–2466.
   PubMed Web of Science ®Google Scholar
• Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388:31–44.
   PubMed Web of Science ®Google Scholar
• Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018 May 21. DOI: 10.1056/NEJMoa1804092.
   Web of Science ®Google Scholar
• Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. DOI: 10.1056/NEJMoa1804093.
   Web of Science ®Google Scholar
• Eshtiaghi P, Gooderham MJ. Dupilumab: an evidence-based review of its potential in the treatment of atopic dermatitis. Core Evid. 2018;13:13–20.
   PubMed Web of Science ®Google Scholar
• Bachert C, Gevaert P, Hellings P. Biotherapeutics in chronic rhinosinusitis with and without Nasal Polyps. J Allergy Clin Immunol Pract. 2017;5:1512–1516.
   PubMed Web of Science ®Google Scholar
• Beck LA, Thaci D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371:130–139.
   PubMed Web of Science ®Google Scholar
• Thaci D, Simpson EL, Beck LA, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2016;387:40–52.
   PubMed Web of Science ®Google Scholar
• Bingefors K, Svensson A, Isacson D, et al. Self-reported lifetime prevalence of atopic dermatitis and co-morbidity with asthma and eczema in adulthood: a population-based cross-sectional survey. Acta Derm Venereol. 2013;93:438–441.
   PubMed Web of Science ®Google Scholar
• Bachert C, Mannent L, Naclerio RM, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA. 2016;315:469–479.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375:2335–2348.
   PubMed Web of Science ®Google Scholar
• Dean K, Niven R. Asthma phenotypes and endotypes: implications for personalised therapy. BioDrugs. 2017;31:393–408. Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• McQueen RB, Sheehan DN, Whittington MD, et al. Cost-effectiveness of biological asthma treatments: a systematic review and recommendations for future economic evaluations. Pharmacoeconomics. 2018. DOI:10.1007/s40273-018-0658-x
   PubMed Web of Science ®Google Scholar
• Hilvering B, Xue L, Pavord ID. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma. Ther Adv Respir Dis. 2015;9:135–145.
   PubMed Web of Science ®Google Scholar
• Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377:936–946.
   PubMed Web of Science ®Google Scholar
• Holgate ST. Innate and adaptive immune responses in asthma. Nat Med. 2012;18:673–683.
   PubMed Web of Science ®Google Scholar
• Aryan Z, Holgate ST, Radzioch D, et al. A new era of targeting the ancient gatekeepers of the immune system: toll-like agonists in the treatment of allergic rhinitis and asthma. Int Arch Allergy Immunol. 2014;164:46–63.
   PubMed Web of Science ®Google Scholar